Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Sonny who wrote (3724)	11/24/2000 10:45:36 AM
From: Gary Mohilner	Respond to of 5665

Thanks Sonny, As TAP Technology proves itself to be an effective way to cure cancer, I believe your 4 split scenario should occur. My estimate would be in about 5 years. It won't stop there of course, but that's a big enough number to make even relatively small investors wealthy in the next 5 years. 5 years from now, IMGN should have 2 to 5 approved drugs, probably 10 to 30 more in clinical trials, and virtually hundreds of drugs pre clinically. Most of these drugs will be in partnerships where others are utilizing TAP Technology to develop drugs, IMGN will see milestone payments and royalties on those. Some of the drugs will be fully developed and majority owned by IMGN, while they'll cost substantial money to bring to market, their income potential is huge. In 5 years IMGN could still be a relatively small sized biotech company, but its pipeline should be huge. Gary